Vendor Intelligence Report: Shaanxi Dideu Medichem

Published 13 Jun 2026. 16-page investigative report on who is behind Shaanxi Dideu Medichem: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Shaanxi Dideu Medichem is a real chemical-supplier counterparty, but the peptide-buyer signal is much narrower than its marketing suggests. Across 8 Finnrick lab tests, the overall pass rate is 63% (5 pass / 3 fail). The tested catalog is retatrutide only, and that line does not behave like a top-tier choice: passes are mixed with repeated failures, and the rating becomes less reassuring under stricter grading focused on tighter fill and purity control.

The corporate trail is equally mixed. Hong Kong and mainland Chinese formation records put the Dideu structure in 2015–2016, while archived captures show the main domain beginning as a generic electronics and fashion storefront before pivoting into chemical/pharmaceutical branding. That record conflicts with a 1975 group-history presentation and with large-scale pharmaceutical-manufacturer positioning.

The report separates legitimacy from peptide suitability. Trade data and academic citations support Dideu as an operating supplier of bulk chemicals, excipients and API-type materials; they do not validate retail research-peptide vials. The most material diligence findings are the gap between public claims and registries, borrowed big-pharma-style language, negative FDA/DMF search results for Dideu names, and a retatrutide record that requires lot-matched verification rather than brand-level trust.

Inside the full report:

  • Per-product Finnrick testing narrative, methodology-divergence chart and Appendix A lab data for the 1 tested product
  • Hong Kong and mainland China registry chronology covering Dideu Industries Group Limited and Shaanxi Dideu Medichem
  • Wayback evidence showing the dideu.com pivot from Foro Shop e-commerce to chemical/pharmaceutical branding
  • Claims-verification analysis comparing Dideu-linked marketing language against Bayer and GSK source text
  • Trade and academic-supplier review separating real chemical-export capability from peptide-specific proof
  • Affiliate and promotion scan documenting company-representative posts and the absence of a swept referral-code network

Risk assessment

  • Retatrutide quality-control risk — high: Finnrick's authoritative record shows 8 retatrutide tests with 5 pass / 3 fail and a 72.46% rating under the public methodology.
  • Misleading corporate-identity claims risk — high: 1975 and 20,000+ employee claims conflict with 2015–2016 registry dates/208 employees; marketing text matches Bayer/GSK sources.
  • Unsupported regulatory-approval claims risk — medium: Dideu-linked listings claim DMF/GMP/COS/FDA status, but FDA DMF/Drugs@FDA searches found no Dideu records; GMP/COS remain unverified.